international technology forum
Transcription
international technology forum
International Technology Forum In vitro-Diagnostics and Bioanalysis 2014 June 12 – 13, 2014 | Berlin | Germany Programme International Technology Forum Perspectives and Challenges of New Biomarker Development Organized by: International Technology Forum Perspectives and Challenges of New Biomarker Development Join our annual meeting and get insights in the latest trends for the development of in vitro-Diagnostics! Scientific Lectures presenting the latest trends in the development of diagnostics Industrial Exhibition showcasing products, services and technologies In cooperation with: Partnering with pre-scheduled one-to-one meetings for companies and research institutes Supported by: Accompanied by Guided Science Tour to Labor Berlin Guided City Tour “Berlin” More Information: www.b2match.eu/techforum2014 International Technology Forum International Technology Forum Perspectives and Challenges of New Biomarker Development Perspectives and Challenges of New Biomarker Development Your partner for next Generation in vitroDiagnostics Welcome The Science & Innovation Team at the British Embassy Berlin is pleased to support this year’s International Technology Forum. We are honoured to have two excellent speakers from the UK highlighting just some of the great work taking place on stratified medicine across the UK. Professor Pirmohamed is chair of the UK’s Pharmacogenetics and Stratified Medicine Network, a research network whose main aim is to develop collaborations between academics, clinicians and industry partners, with the purpose of catalysing research opportunities within the fast growing field of stratified medicine. The Network works closely with the UK’s innovation agency, the Technology Strategy Board, to support expansion and drive forward the aim of making the UK a world leader in stratified medicine. Facing the economical and medical challenges, new biomarkers and innovative diagnostics become more and more significant for the health care systems of the future. As basis for individualized therapy decisions, predictive testing is one of the key drivers for the next generation of in vitrodiagnostics. Antonis Kousoulis is Academic Research Liaison at the Clinical Practice Research Datalink, which is the new English NHS observational data and interventional research service, jointly funded by the NHS National Institute for Health Research (NIHR) and the Medicines and Healthcare products Regulatory Agency (MHRA). CPRD services are designed to maximise the way anonymised NHS clinical data can be linked to enable many types of observational research and deliver research outputs that are beneficial to improving and safeguarding public health. Catapult Centre Network The Technology Strategy Board (TSB) is supporting the setting up of a network of Catapult centres. A Catapult is a technology and innovation centre where the very best of the UK‘s businesses, scientists and engineers can work side by side on research and development, transforming ideas into new products and services to generate economic growth. For many years now, the Berlin-Brandenburg Technology Forum on “In vitro-Diagnostics and Bioanalysis” has been an excellent platform for initiating a sustainable dialogue between fundamental research, industrial development and clinical application. But research and development do not stop on regional borders. So it is with the Technology Forum. Bearing in mind the stronger national and international development, not only the title has been changed – also renowned speakers from Germany and the European Union have been invited to present their latest research. United Kingdom – as this year’s partner country - supported the organizers in the formation of the program. Again, a specially designed partnering event for diagnostic companies and research institutes will facilitate to meet new co-operation partners from Europe for fostering and encouraging possible growth opportunities. Companies will present their latest developments and products during the Industrial Exhibition. Participants will have the opportunity to join a Guided Science Tour to Labor Berlin and a Guided City Tour to Berlin. This June, the International Technology Forum will be once again the place to be for discussing new trends and topics in the area of biomarker and in vitro-diagnostics for neuro-degenerative diseases, pandemia-relevant infection diseases as well as cardiac- and nutritional- related diseases. International Technology Forum International Technology Forum Perspectives and Challenges of New Biomarker Development Programme Perspectives and Challenges of New Biomarker Development Programme Thursday, June 12 Friday, June 13th Guided Science Tour to Labor Berlin (15:00) The laboratories of Charité and Vivantes have been merged into one company: Labor Berlin. In order to go innovative ways in laboratory diagnostics and to provide highest quality services to patients, the competencies of both were combined. Welcome Address (9:00) Rudolf Tauber, Charité – Universitätsmedizin Berlin, Berlin, Germany | Simon Gallagher, British Embassy, Berlin, Germany th Welcome Reception (18:00) Welcome Address Roland Hetzer, Deutsches Herzzentrum Berlin, Berlin, Germany Kai Bindseil, Clustermanager Gesundheitswirtschaft Berlin-Brandenburg – HealthCapital, Germany Welcome Lectures Biomarker Strategy at Sanofi Aventis Kathrin Heermeier, Sanofi Aventis Deutschland GmbH, Frankfurt am Main, Germany Diagnostics and Stratified Medicine in the UK: Changing paradigms in clinics and patient treatment Munir Pirmohamed, University of Liverpool, Liverpool, United Kingdom Opening Lectures Chair: Rudolf Tauber - Universitätsmedizin Berlin 09:15Personalized healthcare 3.0: Vision & implications for in vitro-diagnostics Achim Plum, Siemens AG, Vienna, Austria 09:40Biomarker and personalized medicine – From candidate to clinical application The clinical point of view: Joachim Thiery, Universi-tätsklinikum Leipzig, Leipzig, Germany The industrial point of view: Guido Schütte, Roche Diagnostics Deutschland GmbH, Mannheim, Germany 10:30Coffee Session I: Biomarker and Clinical Research Chair: Joachim Thiery, Universitätsklinikum Leipzig 11:00Key Note: Current needs for the diagnosis of neurodegenerative disorders: Can in vitro tools solve the problem? Etienne Hirsch, Institut Thématique Multi-organismes Neurosciences, Sciences cognitives, Neurologie, Psychiatrie, Paris, France 11.25Towards personalized nutrition – What does it mean for diagnostic demands in the future? International Technology Forum Perspectives and Challenges of New Biomarker Development Hannelore Daniel, Technische Universität München, München, Germany 11.50Non-invasive analysis of cancer genome with circulating tumour DNA Florent Mouliere, University of Cambridge, Cambridge, United Kingdom 12.15The route to diagnostics of relevance in developing countries Mark Perkins, Foundation for Innovative New Diagnostics, Geneva, Switzerland 12.40Lunch Session II: Technology Development Chair: Achim Plum, Siemens AG 13.40Key Note: UK’s leadership position on Stratified Medicine and data protection in the era of Big Data Antonis A. Kousoulis, Clinical Practice Research Datalink (CPRD), London, United Kingdom 14.05Circulating miRNAs and lncRNAs as diagnostic tools in various diseases Thomas Thum, Medizinische Hochschule Hannover, Hannover, Germany 14.30Will glycane based assays become relevant for tumor diagnostics? Véronique Blanchard, Charité – Universitätsmedizin Berlin, Berlin, Germany 14.50T(h)eraDiagnostics platform and perspectives for future development of IVD Frank F. Bier, Fraunhofer IBMT, Potsdam, Germany 15.10Microfluidic flow cytometers for blood cell differentiation International Technology Forum Perspectives and Challenges of New Biomarker Development Jörg Neukammer, Physikalisch-Technische Bundesanstalt, Berlin, Germany 15.30Coffee Session III: Industrial Development – Medical Application Chair: Jens Fuhrmann, Thermo Scientific Biomarkers 16.00 Key Note: Metabolites in heart disease studies Frank Beutner, Herzzentrum Leipzig, Leipzig, Germany 16.20Early diagnosis of heart failure - from discovery to a targeted assay Tim Boelke, Metanomics Health GmbH, Berlin, Germany 16.40Automatic analysis of DNA double strand breaks via ɣH2AX-Foci – A potential marker for individual radioand chemosensitivity Christina Fritz, Medipan GmbH, Dahlewitz, Germany 16.50The vibrant development of IVD industry in China and how to benefit from it Chao Xu, Osmunda Medical Device Service GmbH, Berlin, Germany 17.00 Funding opportunities for Biomarker-research in Horizon 2020 Wolfgang Korek, Berlin Partner für Wirtschaft und Technologie GmbH, Berlin, Germany 17.30 Guided City Tour Join us for a walk through the historical heart of Berlin lead by professional guides just after the Technology Forum. The tour will end in a relaxed dinner. Guided tour is free of charge, dinner is to be paid individually. International Technology Forum Perspectives and Challenges of New Biomarker Development Your benefits from the Partnering Event: ■Showcase your profile to other participants of the event ■Organize yourself: individual pre-scheduled one-to-one meetings with the help of a web-based online tool ■Meet potential business, technological or research partners for future co-operation ■Develop partnerships leading to technological and commercial collaboration ■Establish cross-border contacts for long-term business relationships Biocat Katalonien Barcelona ES BioWales Swansea GB BioWin Wallonia Liège BE Euromediag Languedoc-Roussillon Montpellier FR Life Science Cluster Krakau PL Lyonbiopôle Lyon FR Nexxus East of Scotland Edinburgh GB Oxfordshire Bioscience Network Oxford GB UppsalaBio Uppsala SE ZMDB/Berlin Partner Berlin-Brandenburg DE EDCA unites the strengths of Europe’s diagnostics clusters for scientific excellence and economic growth! Main Objectives »» Facilitating the growth of European SMEs in medical diagnostics »» Promoting cooperations between diagnostic clusters »» Internationalizing of diagnostics development by European collaborative projects Whom you will meet: ■Developers and producers of in vitro-diagnostics ■Service providers ■Suppliers ■Distributors ■Research institutions The earlier you submit your collaboration profile, the more it will be noticed. Participation in the Technology Forum (lectures, industrial exhibition) is free of charge.The fee for the partnering event amounts € 50 (VAT not included).Please note that the Welcome Reception on June 12th, will take place at the Deutsches Herzzentrum Berlin. Due to limited space, participation is only possible on special invitation (interest can be indicated upon registration). More information and registration at: www.b2match.eu/techforum2014 The European Diagnostic Clusters Alliance unites around 400 diagnostic companies in 7 EU countries and is fully supporting the event, making it a real European quality brand for SME-directed diagnostic partnering. Contact Berlin Partner für Wirtschaft und Technologie GmbH Zentrum für Molekulare Diagnostik und Bioanalytik (ZMDB) Dr. Günter Peine info@zmdb.de | www. zmdb.de Venue Charité – Universitätsmedizin Berlin Campus Virchow-Klinikum Forum 3, Lehrgebäude Augustenburger Platz 1 | 13353 Berlin The Center for Molecular Diagnostics and Bioanalysis (ZMDB) is a Flagship Project of the Joint Innovation Strategy Berlin-Brandenburg at Berlin Partner for Business and Technology GmbH. The ZMDB is funded by the states of Berlin and Brandenburg and co-financed by the European Regional Development Fund (ERDF) of the European Union. An investment in your future!